ASP Introduces BIOTRACE™ Instant Read Steam System, Delivering Sterility Assurance in Just Seven Seconds
Current standard biological indicator systems can take 20 minutes or longer to generate a readout. BIOTRACE Instant Read Steam System changes the paradigm by offering SPDs the ability to verify sterilization results nearly immediately, which allows for faster decision-making, improved throughput, and reduced operational strain. In a hospital environment where every minute counts and every load matters, this technology enables confident, real-time transitions from sterilization to documentation.
'The launch of BIOTRACE Instant Read Steam System represents a significant advancement in our ability to deliver fast, actionable sterility data to frontline staff,' said Dr. Ivan Salgo, Vice President and Chief Medical and Scientific Officer at ASP. 'By reducing the readout time to just seconds, we're addressing a long-standing bottleneck that often impacts both productivity and peace of mind. This system supports SPDs not only in meeting compliance standards, but in exceeding them, with confidence.'
Developed with advanced fluorescence detection, BIOTRACE Instant Read Steam System streamlines routine monitoring of steam sterilization cycles without compromising accuracy. The compact reader accommodates two simultaneous test positions, records the last 50 results, and connects seamlessly to digital infrastructure via USB, Wi-Fi, or Bluetooth®. Integration with the BIOTRACE™ Assist App and SM Cloud™ Web Application enables secure cloud storage, enhanced traceability, and automated reporting for hospital instrument tracking systems including CensiTrac™ and other major ITS software solutions.
'ASP is proud to lead the charge in redefining sterility assurance,' said Chad Rohrer, Global President of ASP. 'This is a leap forward in our commitment to help hospitals do more with less, supporting frontline staff with technology that empowers their work. The introduction of BIOTRACE Instant Read Steam System reinforces our role as a trusted partner in innovation for infection prevention, while elevating the standards of care and operational excellence.'
A recent usability study confirmed that throughput and staffing remain top concerns in SPDs nationwide. Respondents cited a strong willingness to invest in time-saving technology, recognizing the value of immediate sterilization verification in high-pressure clinical environments.
Hospitals and health systems can request demos and evaluation kits by contacting their ASP representative.
About Advanced Sterilization Products (ASP)
Advanced Sterilization Products (ASP), a Fortive company, is a global leader in infection prevention dedicated to safeguarding patients during their most critical moments. With a proven history of pioneering low-temperature sterilization and sterility assurance solutions, ASP delivers innovative technologies designed to raise the standard of care across healthcare settings. From terminal sterilization with hydrogen peroxide gas plasma to advanced steam monitoring tools, ASP supports healthcare facilities worldwide in improving efficiency, compliance, and patient safety. For more information, visit www.asp.com.
Advanced Sterilization Products (ASP) and Censis Technologies are subsidiaries of Fortive Corporation. CensiTrac™ software is a product of Censis Technologies.
DISCLOSURE: The third-party trademarks used herein are the properties of their respective owners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Union Pacific Celebrates Its Newest Intermodal Terminal in the Heart of America
The Kansas City Intermodal Terminal provides regional shippers seamless access to growing markets KANSAS CITY, Kan., August 07, 2025--(BUSINESS WIRE)--Union Pacific Railroad celebrated the grand opening of its newest intermodal terminal today in Kansas City, Kansas. This is the fourth intermodal facility Union Pacific has opened since 2021 as part of its ongoing commitment to quickly meet customers' needs and grow the railroad's intermodal footprint. The Kansas City Intermodal Terminal (KCIT) is strategically located near several key highway and interstate arteries that will provide shippers seamless access to Union Pacific's intermodal rail network, with fast, truck-competitive transit times. "This new terminal reflects our commitment to building for the future and providing our customers with convenient and cost-effective access to the U.S. supply chain," said Kenny Rocker, executive vice president-Marketing and Sales at Union Pacific Railroad. "Our customers want faster, more reliable freight options and this terminal delivers." The terminal will serve both domestic and international containerized shipments of grains, consumer goods, refrigerated products, and auto parts in the Midwest region, and will help to convert more truck traffic to rail, which will reduce congestion on the nation's highways and lower greenhouse gas emissions. The new terminal also will significantly increase Union Pacific's local capacity with room available for future growth. It includes two new paved parking lots, additional working tracks for peak efficiency and will feature precision gate technology, providing truckers with automatic entry and exit. Union Pacific also announced it will shift its KCIT domestic service from the Intermodal Container Transfer Facility (ICTF) terminal in Long Beach, California, to the City of Industry terminal in Southern California. Domestic units moving to KCIT will now benefit from Union Pacific's expedited premium network six days a week, offering a more than 25% faster journey and up to 25 hours in savings compared to current industry options, with just over 2.5 days transit. Making the change to City of Industry will complement the KCIT terminal and allow for expanded market access, efficient drayage management and enhanced logistics planning. Units originating in Kansas City will continue to utilize the existing expedited premium train to the City of Industry terminal. ABOUT UNION PACIFIC Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at View source version on Contacts MEDIA CONTACT:Kristen South, Corporate Communications & Media Relationskmsouth@ (402) 544-3435 Sign in to access your portfolio
Business Wire
3 minutes ago
- Business Wire
German American Bank Receives Top 20 Performance Ranking by Bank Director
JASPER, Ind.--(BUSINESS WIRE)--German American Bank (Nasdaq: GABC) has been ranked in the country's Top 20 for its banking performance in the $5 billion to $50 billion asset size by Bank Director's 2025 RankingBanking study. Each year, Bank Director ranks the 300 largest publicly traded banks based on profitability, capital adequacy and asset quality for the previous year. 'Receiving a top 20 ranking is a testament to our steadfast strategic focus on long-term results for our shareholders, employees, customers and the communities we serve,' states Neil Dauby, Chairman and CEO. 'Such a high ranking demonstrates our Company's financial focus, strength and stability. Since 1910, German American Bank has been a pillar within the communities we serve. Our focus is to ensure our communities have local bankers who can help local people and businesses achieve their financial goals and dreams and improve their quality of life and place.' Since 1991, Bank Director has been a resource to the leaders of the financial industry by providing board-level research, peer insights and in-depth executive and board services. The organization also provides timely and relevant information through Bank Director magazine. The 2025 RankingBanking study was published in their August 2025 edition. About German American German American Bancorp, Inc. (Nasdaq: GABC) is a $8.3 billion financial holding company. Through its banking subsidiary, German American Bank, it provides a wide range of banking and wealth management services to businesses and individuals in 94 offices across central and southern Indiana; northern, central and western Kentucky; and central and southwest Ohio. In the Columbus Ohio and Greater Cincinnati markets, the Company does business as Heartland Bank, a division of German American Bank. The Company also owns an investment brokerage subsidiary, German American Investment Services, Inc.
Business Wire
3 minutes ago
- Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) securities between , inclusive (the 'Class Period'). Novo Nordisk investors have until September 30, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR NOVO NORDISK A/S (NVO) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS What Happened? On July 29, 2025, Novo Nordisk cut its previously issued fiscal year 2025 guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize upon the purported significant unmet patient population; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Novo Nordisk securities during the Class Period, you may move the Court no later than September 30, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
